Details of the Drug Formulations

General Information of Drug (ID: DM2R86O)

Drug Name
Siponimod Drug Info
Synonyms BAF312
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Approved [1]
Hepatocellular carcinoma 2C12.02 Phase 3 [2]
Rheumatoid arthritis FA20 Phase 2 [3]
Cross-matching ID
PubChem CID
44599207
CAS Number
1230487-00-9
TTD ID
D07FKQ
VARIDT ID
DR00743
INTEDE ID
DR1488
ACDINA ID
D01430

Full List of Drug Formulations Containing This Drug

Siponimod 0.25mg tablet
Company Formulation ID FDA Description
Novartis Pharmaceuticals Corporation F23895 Colloidal Silicon Dioxide; Crospovidone; Glyceryl Behenate; Lactose Monohydrate; Microcrystalline Cellulose; Black Iron Oxides; Red Iron Oxides; Lecithin (Soy); Polyvinyl Alcohol; Talc; Titanium Dioxide; Xanthan Gum
------------------------------------------------------------------------------------
Siponimod 2mg tablet
Company Formulation ID FDA Description
Novartis Pharmaceuticals Corporation F23896 Colloidal Silicon Dioxide; Crospovidone; Glyceryl Behenate; Lactose Monohydrate; Microcrystalline Cellulose; Red Iron Oxides; Yellow Iron Oxides; Lecithin (Soy); Polyvinyl Alcohol; Talc; Titanium Dioxide; Xanthan Gum
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 ClinicalTrials.gov (NCT01665144) Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)